Abstract: A new intermediate for synthesizing 1-substituted-4-[phenyl(propanoyl)amino]piperidine-4-carbonitrile derivatives is laid open. Specifically set out is a method for use of this intermediate in the preparation of remifentanil. The enclosed shorter process offers a greater yield of products with higher purity as compared to methods reported in the prior art.

Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin to an E-selectin ligand are disclosed. For example, haloalkyl fucose-containing E-selectin antagonists and compositions comprising at least one such agent are described.

Abstract: A new intermediate for synthesizing 1-substituted-4-[phenyl(propanoyl)amino]piperidine-4-carbonitrile derivatives is laid open. Specifically set out is a method for use of this intermediate in the preparation of remifentanil. The enclosed shorter process offers a greater yield of products with higher purity as compared to methods reported in the prior art.

Abstract: The present invention relates to a method of forming a sealed channel on the surface of a sheet made of a material with a particular extent of plasticity, the sheet forming a reactor block for a microfluidic reactor.

Abstract: The present invention generally relates to compounds and pharmaceutical compositions containing the compounds. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).

Abstract: A flow-type laboratory scale ozonolysis apparatus (100) according to the invention comprises a reservoir (104), a n feed pump (102), a mixing element (120) with two inlets and an outlet, a reactor unit (110) and a pressure-adjusting means (160), all connected into a flow path. The ozonolysis apparatus (100) further comprises an ozone source (110), as well as a dispensing valve (112) transmitting a gas stream only in a single direction and installed between the ozone source (110) and one of the inlets of the mixing element (120). The feed pump (102) of the ozonolysis apparatus (100) according to the invention is a liquid pump generating a constant volume rate, the reservoir (104) contains at least the substance, as a solute, to be subjected to the ozonolysis reaction and the reactor unit consists of first and second reactor zones differing in function from one another. In the flow path, the outlet of the first reactor zone is connected to the inlet of the second reactor zone.

Abstract: In a method according to the invention for forming a sealed channel (125) in the surface of a sheet made of a material with certain extent of plasticity, the machining surface of a tool with a rolling machining surface is brought into contact with a first point of the channel (125) to be formed in the surface of the sheet constituting a reactor block. Next, said machining surface is pressed onto the surface of the sheet with a compressive force (F) required to achieve the depth of the channel (125) to be formed, whereby the plastic material is squeezed out and becomes raised from the sheet surface on the peripheries of the depression being formed.

Abstract: The ozone generating electrolysis cell (10) according to the invention has a negative electrode (13) and an ozone generating positive electrode (16) comprising a mixture of lead dioxide and polytetrafluoroethylene (PTFE). A proton conducting solid electrolytic membrane (15) is arranged between the negative and positive electrodes (13, 16). The ozone generating electrolysis cell (10) also comprises an electrically conducting, liquid and gas permeable first electrode support (17) in contact with a side of the positive electrode (16) located opposite to the membrane (15), wherein said side of the electrode support (17) has a surface covered with a platinum-containing layer. The positive electrode (16) is made of a mixture prepared by the high-pressure compression of lead dioxide grains of colloid size and PTFE filaments having a dimension of at most 1 mm.

Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).